Company Profile
Chiasma Inc
Company Overview
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In July 2019, the Company reported positive top-line data from its completed Phase 3 clinical trial of its octreotide capsules product candidate, conditionally trade named MYCAPSSA, for the maintenance therapy of adult patients with acromegaly. In January 2020, the FDA accepted for review the resubmission of Chiasma’s New Drug Application seeking marketing approval for MYCAPSSA in the United States and assigned PDUFA action date of June 26, 2020. The Company is also currently conducting a Phase 3 multinational clinical study designed for EMA commercial approval. Chiasma is headquartered in Needham, MA with a wholly owned Israeli subsidiary.